SynthesisClinical pharmacokinetics2013
Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis.
Synthesis in Clinical pharmacokinetics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Altered intravenous drug disposition in people living with cystic fibrosis: A meta-analysis integrating top-down and bottom-up data.CPT: pharmacometrics & systems pharmacology · 2022Pooled it
- Antibiotics in Adult Cystic Fibrosis Patients: A Review of Population Pharmacokinetic Analyses.Clinical pharmacokinetics · 2021Pooled it
- Pharmacokinetics in Patients with Cystic Fibrosis: A Systematic Review of Data Published Between 1999 and 2019.Clinical pharmacokinetics · 2020Pooled it
- A systematic review of population pharmacokinetic analyses of digoxin in the paediatric population.British journal of clinical pharmacology · 2020Pooled it
- On target dosing: erythropoietin exposure in neonates with hypoxic-ischemic encephalopathy in the HEAL trial.Pediatric research · 2025Trial
- Dosing of Ceftriaxone and Metronidazole for Children With Severe Acute Malnutrition.Clinical pharmacology and therapeutics · 2018Trial
- One Model to Dose Them All: A Population Pharmacokinetic Model for Multiple Aminoglycosides Across the Human Lifespan.Journal of clinical pharmacology · 2026Article
- Pharmacokinetic analysis of conventional tobramycin dosing for infants in the cardiac intensive care unit.Pediatric research · 2026Article
- Hitting the Target: Model-Informed Precision Dosing of Tobramycin in Pediatric Patients with Cystic Fibrosis.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Personalized tobramycin dosing in children with cystic fibrosis: an AUCAntimicrobial agents and chemotherapy · 2025Observational
- Anti-infectives in Pediatric Patients with Cystic Fibrosis: A Comprehensive Review of Population Pharmacokinetic Analyses.Clinical pharmacokinetics · 2025Review
- Comparing two-sample log-linear exposure estimation with Bayesian model-informed precision dosing of tobramycin in adult patients with cystic fibrosis.Antimicrobial agents and chemotherapy · 2025Article
- Therapeutic Interventions forJournal of clinical medicine · 2024Review
- Probability of Target Attainment of Tobramycin Treatment in Acute and ChronicPharmaceutics · 2022Article
- Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.Antimicrobial agents and chemotherapy · 2022Article
- Defining the Importance of Age-Related Changes in Drug Clearance to Optimizing Aminoglycoside Dosing Regimens for Adult Patients with Cystic Fibrosis.European journal of drug metabolism and pharmacokinetics · 2022Article
- Pharmacokinetic modelling to predict risk of ototoxicity with intravenous tobramycin treatment in cystic fibrosis.The Journal of antimicrobial chemotherapy · 2021Article
- Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?Antibiotics (Basel, Switzerland) · 2021Review
- Pharmacokinetic and Pharmacodynamic Optimization of Antibiotic Therapy in Cystic Fibrosis Patients: Current Evidences, Gaps in Knowledge and Future Directions.Clinical pharmacokinetics · 2021Review
- The Utility of Pharmacometric Models in Clinical Pharmacology Research in Infants.Current pharmacology reports · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
Abstract
BACKGROUND AND
objectivesWhile several studies have examined the pharmacokinetics of tobramycin in patients with cystic fibrosis (CF), there is no consensus on whether they differ in patients with and without CF. The objectives of this study were to identify covariates which explain pharmacokinetic variability and to examine whether having the disease CF in itself alters these relationships and drug dose requirements.
methodsTo investigate this issue, a population pharmacokinetic meta-analysis of data from eight centres was undertaken. NONMEM(®) 7.2 was used to analyse the data, which comprised 4,514 concentration-time measurements from 465 adults and children with CF and 1,095 concentration-time measurements from 267 adults and children without CF.
resultsTobramycin disposition was well described by a two-compartment model with first-order elimination. Patient age, fat-free mass, serum creatinine concentration and sex were identified as significant covariates in the final model. Fat-free mass was superior to total bodyweight as a descriptor of clearance, volume of distribution of the central and peripheral compartments and inter-compartmental clearance. CF as an independent disease-specific factor had no significant influence on the pharmacokinetics of tobramycin at any stage during covariate model building. An optimal dose of 11 mg/kg every 24 h was defined for CF patients using a utility function approach.
conclusionThe pharmacokinetics of tobramycin do not differ significantly in CF patients compared with patients without CF when subject age, fat-free mass, sex and renal function are taken into consideration. Variations in tobramycin dosing between CF and non-CF patients should therefore reflect target concentrations or exposures based on differences in expected pathogen sensitivity and not the presence of CF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.